Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTW-002 in Dystrophic Epidermolysis Bullosa
NCT05529134Phase 2Unknown
- Sponsor
- Phoenicis Therapeutics
- Start
- Apr 2023
- Primary completion
- Apr 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of QR-313 in dystrophic epidermolysis bullosa (DEB), sponsored by Phoenicis Therapeutics. Status: unknown.
02
Drugs
QR-313
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT05529134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05529134.